Investment Rating - The report indicates a positive investment outlook for the pharmaceutical and biotechnology sector, particularly focusing on PD-1/VEGF dual antibodies [1]. Core Insights - The pharmaceutical and biotechnology sector saw a weekly increase of 3.64%, outperforming the Shanghai Composite Index (1.54%) and the Wind All A Index (1.22%). The PD-1/VEGF related stocks led the gains, with other biopharmaceuticals rising by 8.28% [2][7]. - A significant partnership was announced between Bristol-Myers Squibb (BMS) and BioNTech, involving a $11.1 billion agreement to co-develop and commercialize BioNTech's PD-L1/VEGF dual-specific antibody BNT327. This highlights the strategic importance of PD-1/VEGF dual antibodies in the global market [2][3]. - The report emphasizes the increasing interest from multinational corporations (MNCs) in the PD-1/VEGF dual antibody space, suggesting that domestic biotech firms are well-positioned for future business development (BD) opportunities [2][3]. Summary by Sections Market Weekly Review - The pharmaceutical and biotechnology sector experienced a 3.64% increase, with notable performances from individual stocks such as Seer Medical (51.5%), Guangsheng Tang (48.6%), and Shenzhou Cell-U (45%) [7][10]. - The report notes that the other biopharmaceuticals sector rose by 8.28%, while medical devices and hospitals saw slight declines [2][7]. Industry News and Key Company Announcements - On July 1, the National Healthcare Security Administration released proposals for the adjustment of the 2025 National Basic Medical Insurance drug catalog, aiming to support innovative drug development [12]. - Significant approvals were noted, including the launch of TQG203 for treating hemophilia and the approval of Liraglutide for obstructive sleep apnea [12][13]. - Strategic investments were highlighted, such as Sanofi's investment in Tianyan Pharmaceutical, which will support the development of SAFEbody antibodies [15]. Company Announcements - Several companies reported significant developments, including the approval of new drugs and strategic partnerships aimed at enhancing their market positions [15][16]. - Notably, the report mentions the approval of innovative drugs that address unmet medical needs, indicating a trend towards more targeted therapies in the market [12][13].

Core Viewpoint - Junshi Bioscience plans to raise approximately HKD 1.039 billion through the placement of 41 million new H-shares at a price of HKD 25.35 per share, which represents an 11.52% discount to the closing price on June 12 [1] Group 1: Fundraising and Use of Proceeds - The company intends to allocate 70% of the raised funds for innovative drug development, focusing on dual-specific antibodies such as JS207 (PD-1/VEGF), JS212 (EGFR/HER3), and JS213 (PD-1/IL-2) [1] - The remaining funds will be used to supplement working capital [1] - Junshi Bioscience previously announced an investment of CNY 767 million in the PD-1/VEGF dual antibody (JS207) [1] Group 2: Clinical Development and Market Position - JS207 is currently in Phase II clinical trials, with plans to conduct key clinical trials for lung cancer, breast cancer, liver cancer, colorectal cancer, and other advanced solid tumors [1] - Junshi Bioscience, established in December 2012, was the first domestic company to receive approval for a PD-1 monoclonal antibody, but its product, Toripalimab, has faced stiff competition from later entrants [4] - Toripalimab remains the company's leading product, generating CNY 1.501 billion in domestic sales in 2024, accounting for 77% of total revenue of CNY 1.948 billion [4] Group 3: Financial Performance and Market Trends - Despite not yet achieving profitability, the company's losses have significantly narrowed in 2024, with Q1 revenue and net loss reported at CNY 500 million and CNY 235 million, respectively [4] - The PD-1/VEGF dual antibody field has gained traction, with significant competitive developments, including a head-to-head trial where a competitor's product outperformed the leading PD-1 drug [5] - The innovative drug sector has seen a strong performance in the A-share market, with a 12.72% increase in May and a total increase of over 22% from April to June [6]

Core Viewpoint - The recent $11.1 billion deal between Bristol-Myers Squibb (BMS) and BioNTech for the development of the dual-specific antibody BNT327 has sparked significant interest in the pharmaceutical industry, raising questions about the valuation of Chinese innovative drugs in the global market [3][4]. Group 1: Transaction Details - BMS will pay BioNTech an upfront payment of $1.5 billion and up to $7.6 billion in additional milestone payments, potentially bringing the total deal value to $11.1 billion [4]. - BNT327 is currently undergoing multiple Phase III clinical trials, with over 1,000 patients enrolled, targeting various solid tumors [6]. - BioNTech acquired BNT327 from Chinese biotech firm Primus Biotech in two transactions, totaling a potential deal value of $2.005 billion [7]. Group 2: Market Dynamics - The PD-L1/VEGF dual antibody market has gained traction due to its potential to outperform existing therapies, leading to increased interest from major pharmaceutical companies [9]. - The "Newco" model of licensing, where smaller biotech firms sell rights to intermediaries who then resell to larger companies, is becoming more prevalent in the industry [11][12]. - The perception that Chinese innovative drugs are being sold at a loss is challenged by the evolving market conditions and the associated risks at the time of the original transactions [8][12]. Group 3: Future Outlook - As Chinese biotech firms gain recognition for their innovative capabilities, the negotiation power and trust with multinational companies are expected to improve, potentially leading to higher valuations in future transactions [13].

Group 1 - The core point of the news is that 3SBio has sold its PD-1/VEGF dual antibody SSGJ-707 to Pfizer for a record upfront payment of $1.25 billion and has initiated a Phase III clinical trial for the drug targeting advanced PD-L1 positive non-small cell lung cancer (NSCLC) [1][2] - The Phase III trial will enroll 420 patients and is expected to start in June 2023, with preliminary results anticipated by July 2026. The primary endpoint is progression-free survival (PFS) and the secondary endpoint is overall survival (OS) [1] - SSGJ-707 has received breakthrough therapy designation from the National Medical Products Administration (NMPA) in China, and its combination therapy indication is still in Phase II [1] Group 2 - The competitive landscape shows that PD-1/VEGF dual antibodies are becoming a popular choice among pharmaceutical companies, with 3SBio's stock price rising over 9% following the announcement of the deal with Pfizer, leading to a market capitalization exceeding HKD 50 billion [2] - The global sales of the leading PD-1 drug, pembrolizumab (K drug), are projected to be around $25 billion in 2023 and $29 billion in 2024, making it a significant competitor for new entrants like SSGJ-707 [3] - The head-to-head clinical trial results of another PD-1/VEGF dual antibody, Ivosidenib, against pembrolizumab have shown a median PFS of 11.14 months compared to 5.82 months for pembrolizumab, indicating potential advantages for dual antibodies [3] Group 3 - The current treatment guidelines recommend pembrolizumab as a first-line therapy for advanced non-squamous NSCLC, particularly for patients with high PD-L1 expression [4] - The approval process for new drugs requires demonstrating superior efficacy compared to existing treatments, which poses a challenge for both 3SBio and other companies developing similar products [4][5] - The financial implications for companies like 3SBio and Akeso are significant, as they invest heavily in R&D, with Akeso's R&D expenses exceeding 1 billion yuan in 2023 and 2024 [5]

Group 1 - The Hong Kong pharmaceutical ETF (513700.SH) has risen by 1.34%, reaching a new high of 1.038 billion yuan, with major constituent stocks like Kangfang Biotech up 6.07% and WuXi Biologics up 3.11% [1] - Recently, 3SBio entered a licensing agreement with Pfizer for the PD-1/VEGF dual antibody SSGJ-707, granting Pfizer global rights outside of mainland China, with 3SBio receiving an upfront payment of $1.25 billion and potential milestone payments of up to $4.8 billion, along with royalties [1] - The only remaining PD-1/VEGF pipeline in China currently in Phase II clinical trials is RC148 from Rongchang Biotech, which is based on the Hibody dual antibody technology platform and is expected to enter Phase I clinical trials for treating advanced malignant solid tumors by July 2024 [1] Group 2 - Rongchang Biotech is in discussions for multiple collaborations with various companies, and there is speculation that RC148 may also attract interest from overseas pharmaceutical giants, similar to other companies in the PD-1/VEGF dual antibody space [2] - According to Zhongtai Securities, the pharmaceutical and biotechnology industry is experiencing rapid thematic opportunities due to diverse external policy changes, with recent positive developments in US-China tariff policies alleviating pessimism [2] - The firm maintains an "overweight" rating for the pharmaceutical and biotechnology sector, particularly highlighting 3SBio among Hong Kong Stock Connect pharmaceutical constituents as a "buy" recommendation, suggesting that policy changes will create structural opportunities in the industry [2]